Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°íÇü¾Ï ³úÀüÀ̽à ¹æ»ç¼±Ä¡·á È¿°ú The Role of Radiotherapy in Patients with Brain Metastasis

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1999³â 17±Ç 4È£ p.281 ~ 286
¼Ò¼Ó »ó¼¼Á¤º¸
1À̼ø³²/1Soon Nam Lee 1Áֹ̼ø/2ÀÌ°æÀÚ/3³²Àº¹Ì/1Mi Soon Choo/2Kyung ja Lee/3Eunmi Nam

Abstract

¹è°æ ¹× ¸ñÀû : °íÇü¾ÏÀÇ ³úÀüÀÌ´Â 20¡­40%ÀÇ ¾ÏȯÀÚ¿¡¼­ ¹ß»ýÇÏ°í, ³úÀüÀÌ ÈÄ 1³â »ýÁ¸À²Àº
15%Á¤µµ·Î ¿¹ÈÄ°¡ ºÒ·®ÇÏ¸ç °í½ÄÀû ¹æ»ç¼±Ä¡·á µî¿¡ ÀÇÇÏ¿© 70¡­90%ÀÇ È¯ÀÚ¿¡¼­ Áõ»óÀÌ È£ÀüµÇ
³ª ´ëºÎºÐÀÇ È¯ÀÚ°¡ °á±¹Àº ³úÀüÀÌ·Î ÀÎÇÏ¿© »ç¸ÁÇÏ°Ô µÈ´Ù. ÀÌ¿¡ °íÇü¾ÏÀÇ ³úÀüÀÌ·Î ¹æ»ç¼±Ä¡·á
¸¦ ¹ÞÀº ȯÀÚ¸¦ ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿© ÀÓ»ó¾ç»ó°ú »ýÁ¸±â°£À» ºÐ¼®ÇÏ°í ¿¹ÈÄÀÎÀÚ¸¦ ÆľÇÇÏ¿´´Ù.
¹æ¹ý : ´ë»óȯÀÚ´Â 1987³â 1¿ùºÎÅÍ 1998³â 1¿ù±îÁö ÀÌÈ­¿©ÀÚ´ëÇб³ ºÎ¼Óº´¿ø¿¡¼­ °íÇü¾ÏÀÇ ³úÀü
ÀÌ·Î °í½ÄÀû Àü³ú ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 71¿¹À̾ú´Ù. ´ë»ó ȯÀÚÀÇ Áß¾Ó¿¬·ÉÀº 63¼¼(24¡­89¼¼)¿´°í ³²
ÀÚ 50¿¹, ¿©ÀÚ 21¿¹À̾ú´Ù. °í½ÄÀû Ä¡·á ÈÄ ½Å°æÁõ»óÀÇ È£ÀüÁ¤µµ¸¦ Æò°¡ÇÏ°í, ¿¬·É, Á¾¾çÀÇ ¿ø¹ßº´
¼Ò, Áø´Ü ´ç½Ã ³úÀüÀÌ µ¿¹Ý À¯¹«, ŸÀå±â ÀüÀÌ À¯¹«, ³úÀüÀÌ º´º¯ ¼ö, Ä¡·á¹æ¹ý¿¡ µû¶ó »ýÁ¸±â°£À»
ºñ±³ÇÏ¿´´Ù.
°á°ú : ³úÀüÀ̽à µ¿¹ÝµÈ Áõ»óÀº µÎÅëÀÌ 34¿¹·Î °¡Àå ¸¹¾ÒÀ¸¸ç ±Ù·Â ¾àÈ­ 29¿¹, ¿À½É ±¸Åä ¹× ÀÇ
½Äº¯È­ °¢ 14¿¹, ½Ã·ÂÀå¾Ö 8¿¹, ±¸À½Àå¾Ö 7¿¹¼øÀ̾ú°í Ä¡·á ÈÄ ½Å°æÁõ»óÀÇ È£ÀüÀº 64.9%¿¡¼­ °ü
ÂûµÇ¾ú´Ù. ³úÀüÀÌÀÇ Ä¡·á·Î ÀüüȯÀÚ Áß 7¿¹¿¡¼­´Â ³úÀüÀÌÀÇ ¼ö¼úÀû Á¦°Å ÈÄ Àü³ú ¹æ»ç¼±Ä¡·á¸¦
¹Þ¾Ò°í ³ª¸ÓÁö 64¿¹´Â Àü³ú ¹æ»ç¼±Ä¡·á¸¸À» ¹Þ¾Ò´Ù. ÀüüȯÀÚÀÇ Áß¾Ó»ýÁ¸±â°£Àº 16ÁÖ¿´°í 1³â »ý
Á¸À²Àº 15.0%, 2³â »ýÁ¸À²Àº 5.1%¿´´Ù. ŸÀå±â ÀüÀÌ°¡ ¾øÀÌ ³úÀüÀÌ ´Üµ¶ÀÎ ±º(n=27)ÀÇ Áß¾Ó»ýÁ¸
±â°£Àº 33ÁַΠŸÀå±â ÀüÀÌ°¡ ÀÖ´Â ±ºÀÇ 10ÁÖ¿¡ ºñÇØ ±æ¾ú´Ù(p=0.0018). ³úÀüÀÌ ¼ö°¡ ´ÜÀÏ º´¼ÒÀÎ
37¿¹ÀÇ È¯ÀÚ¿¡¼­´Â ¼ö¼úÀû Á¦°Å ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ÇÑ ±º(n=7)ÀÇ Áß¾Ó»ýÁ¸±â°£ÀÌ 40ÁÖ·Î ¹æ»ç¼±Ä¡
·á¸¸ ½ÃÇàÇÑ ±ºÀÇ 16ÁÖ¿¡ ºñÇØ ±æ¾ú´Ù(p=00438). ÀÌ¿Ü¿¡ ¿¬·É, ¿ø¹ß¾ÏÀÇ Á¾·ù, Àü½Å¼öÇà »óÅÂ, Áø
´Ü´ç½Ã ³úÀüÀÌ µ¿¹Ý À¯¹«, ³úÀüÀÌ º´º¯ ¼ö¿¡ µû¸¥ »ýÁ¸±â°£ÀÇ Â÷ÀÌ´Â ¾ø¾ú´Ù.
°á·Ð : °íÇü¾Ï¿¡¼­ ³úÀüÀÌ´Â ³ª»Û ¿¹ÈÄÀÎÀÚÀ̳ª ³ú·ÎÀÇ ´Üµ¶ÀüÀ̴ ŸÀå±â ÀüÀÌ µ¿¹Ý¿¡ ºñÇØ ¿¹
ÈÄ°¡ ¾çÈ£ÇϹǷΠ¼ö¼úÀû ÀýÁ¦, ¹æ»ç¼±Ä¡·á µîÀÇ ´Ù¾çÇÑ ¹æ¹ýÀ» ÀÌ¿ëÇÑ º¸´Ù Àû±ØÀûÀÎ Ä¡·á·Î »ý
Á¸À² ¹× »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖÀ» °ÍÀÌ´Ù.

Purpose : Brain metastases are the most frequent metastatic neurologic complication of
systemic cancer. Even if the prognosis of brain metastases is grave, with available
treatments, most patients experience effective palliation of neurologic symptoms and
meaningful extension of life. We evaluated the clinical features and prognostic factors of the
patients who were diagnosed as solid tumors with brain metastasis and received radiotherapy
for brain metastases.
Materials and methods : Between January 1987 and January 1998, 71 patients with brain
metastases from solid malignancy were included. We reviewed neurologic symptoms and signs
of patients and evaluated improvement of neurologic symptoms and signs. Survival durations
after brain metastasis were analysed according to several factors such as age, performance
status, primary malignancies, the presence of brain metastasis at initial diagnosis of primary
tumor, multiplicity of brain metastass, the presence of metastases other than brain, and
treatment method.
Results : Frequent symptoms associated with brain metastasis were headache(47.9£¥), motor
weakness(40.8£¥), nausea and vomiting(19.7£¥) and mental change(19.7£¥). Palliation of these
symptoms was accomplished in 64.9£¥ of cases. The overall median survival time was 16
weeks and 1-and 2-year survival rates were 15.0£¥ and 5.1£¥ respectively. Patients without
extracranial metastases (n=27) had longer median survival than patients with extracranial
metastases (33 weeks vs 10 weeks, p=0.0018). In patients with single brain metastasis (n=37),
the median survival time was longer in patients treated with surgery plus radiotherapy than
in patients treated with radiotherapy alone (40 weeks vs 16 weeks, p=0.0438).
Conclusion : Patients who has brain metastases only constitute a prognostically favorable
group and they may be benefited from radiotherapy and surgery if indicated.

Å°¿öµå

°íÇü¾Ï; ³úÀüÀÌ; ¹æ»ç¼±Ä¡·á; ¿¹ÈÄÀÎÀÚ; Brain metastases; Radiation therapy; Prognostic;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS